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ABSTRACT Cellular senescence is a widespread stress response and is widely considered to 
be an alternative cancer therapeutic goal. Unlike apoptosis, senescence is composed of a 
diverse set of subphenotypes, depending on which of its associated effector programs are 
engaged. Here we establish a simple and sensitive cell-based prosenescence screen with 
detailed validation assays. We characterize the screen using a focused tool compound kinase 
inhibitor library. We identify a series of compounds that induce different types of senescence, 
including a unique phenotype associated with irregularly shaped nuclei and the progressive 
accumulation of G1 tetraploidy in human diploid fibroblasts. Downstream analyses show that 
all of the compounds that induce tetraploid senescence inhibit Aurora kinase B (AURKB). 
AURKB is the catalytic component of the chromosome passenger complex, which is involved 
in correct chromosome alignment and segregation, the spindle assembly checkpoint, and 
cytokinesis. Although aberrant mitosis and senescence have been linked, a specific character-
ization of AURKB in the context of senescence is still required. This proof-of-principle study 
suggests that our protocol is capable of amplifying tetraploid senescence, which can be ob-
served in only a small population of oncogenic RAS-induced senescence, and provides addi-
tional justification for AURKB as a cancer therapeutic target.
INTRODUCTION
Cellular senescence is a state of stable or “irreversible” cell cycle 
arrest induced by various cytotoxic factors, including telomere dys-
function, DNA damage, oxidative stress, oncogenic stress, and 
some types of cytokines (Correia-Melo et al., 2014; Salama et al., 
2014) Although senescence was originally defined in normal human 
diploid fibroblasts (HDFs)—the best-characterized culture model of 
senescence—a similar phenotype can be induced in a wide range of 
cell types, as well as in in vivo contexts that are associated with vari-
ous pathophysiological conditions, such as tumorigenesis (Pérez-
Mancera et al., 2014), tissue repair (Krizhanovsky et al., 2008; Jun 
and Lau, 2010), aging (López-Otín et al., 2013), and, more recently, 
embryogenesis (Chuprin et al., 2013; Muñoz-Espín et al., 2013; 
Storer et al., 2013). Of these, oncogene-induced senescence, in 
which excessive mitogenic stress provokes senescence effectors 
leading to progressive development of senescence phenotypes in 
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AURKB in normal HDFs induces senescence (Jung et al., 2005). A 
more recent study, however, reported that AURKB overexpression 
delays senescence, and small interfering RNA–mediated AURKB 
knockdown induces senescence in HDFs (Kim et al., 2011). Thus 
there is room for a more detailed characterization of the senescence 
phenotype caused by the modulation of AURKB expression and, 
more specifically, its enzymatic activity.
Owing to the diverse nature of senescence, identifying or devel-
oping senescence-inducing factors not only would extend our 
cancer therapeutic modalities, it would also help in elucidating the 
effector mechanisms of senescence. Although numerous genetic 
“senescence bypass” screens have been successfully conducted 
(Jacobs et al., 2000; Shvarts et al., 2002; Gil et al., 2004; Acosta 
et al., 2008; Kortlever et al., 2008; Leal et al., 2008; Rovillain et al., 
2011), attempts at “senescence-inducing” screens are limited 
(Ewald et al., 2009; Lahtela et al., 2013). Here, taking advantage of 
a high-content fluorescence image analyzing system, we set out 
simple primary screens for small molecules that can induce senes-
cence-related nuclear phenotypes, namely an enlargement in nu-
clear size and SAHF-like chromatin spottiness, in HDFs, followed by 
secondary analyses for detailed senescence validation in both HDFs 
and tumor cell lines. Using a kinase inhibitor library, we identify 
compounds that induce senescence with different nuclear morphol-
ogies. Of interest, although the substrate specificities of the kinase 
inhibitors used were rather limited, a subset of the hit compounds 
converged on AURKB to induce a unique senescence phenotype, in 
which G1 tetraploidy or polyploidy progressively accumulated. Our 
study provides a simple and sensitive prosenescence screen, and 
the data reinforce the relevance of AURKB as a cancer therapeutic 
target.
RESULTS
Identification of small-molecule compounds that induce 
senescence-associated morphological changes in nuclei
To establish an image-based screen for senescence inducers, we 
focused on senescence-associated nuclear morphological changes 
as our readout, using high-throughput fluorescent microscopy 
(Figure 1A). We chose IMR90 HDFs, which are generally more sensi-
tive to senescence than apoptosis in response to cellular stress and 
have thus been well characterized in terms of senescence (Serrano 
et al., 1997; Narita et al., 2003). To optimize the protocol for image 
acquisition and the analyses of nuclear size and nuclear foci (spots), 
we used normal and HRASG12V-induced senescent cells, which ex-
hibit prominent SAHFs (Figure 1B; Narita et al., 2003). Cells were 
plated on 96-well plates, fixed, and stained with 4′,6-diamidino-
2-phenylindole (DAPI) for the automated imaging of nuclei (Supple-
mental Figure S1 and Supplemental Table S1).
Using this system, we treated normal proliferating IMR90 cells 
with 160 kinase inhibitors (InhibitorSelect; Calbiochem/Merck) and 
quantified both the nuclear size and the area of any subnuclear foci 
per nucleus (Figure 1C). The scores from each well were normalized 
to those from the dimethyl sulfoxide (DMSO) controls, and the hits 
were determined by setting a threshold of either 1.2-fold (“relative 
nuclear average area”) or threefold (“relative spot total area per 
nucleus”) above the control. Of 160 compounds (tested at a stan-
dardized 5 μM), 11 and 17, scored positive for nuclear size (large) 
and spottiness (spotty), respectively, with substantial overlap (Figure 
1D and Supplemental Tables S2 and S3). Cells with an enlarged or 
spotty nucleus tended to show a low relative object count per field, 
which reflected the averaged cell density in the area scanned (Sup-
plemental Figure S1C), suggesting that those hit compounds have 
antiproliferative and/or procell death activity. Similar results were 
culture and animal models, underscores the tumor suppressor role 
of senescence. In addition, it has been shown that senescence can 
also be induced by chemotherapeutic reagents in tumors (therapy-
induced senescence [TIS]), particularly in apoptosis-defective con-
texts (Poele et al., 2002; Schmitt et al., 2002; Xue et al., 2007; 
Gewirtz et al., 2008; Ewald et al., 2010; Dörr et al., 2013). Therefore 
senescence has been considered as not only an intrinsic tumor sup-
pressor, but also an alternative therapeutic goal in cancer (Acosta 
and Gil, 2012; Cairney et al., 2012). However, it has been shown that 
senescence may also facilitate tumorigenesis: senescent cells often 
secrete a wide range of soluble factors, which have a considerable 
effect on the tumor microenvironment and local immune response, 
providing antitumorigenic and/or protumorigenic effects, depend-
ing on the context (Coppé et al., 2010; Pérez-Mancera et al., 2014).
Senescence is typically a dynamic and long-term process, which 
can involve many regulatory effector mechanisms, conferring a di-
verse and heterogeneous nature on the phenotype (Salama et al., 
2014). Thus, to evaluate qualitatively the senescence phenotype, 
various cellular and biochemical markers have been identified. 
Senescence markers include accumulation of senescence-associ-
ated β-galactosidase (SA-β-gal) activity, a persistent DNA-damage 
response, the senescence-associated secretory phenotype (SASP; 
Kuilman and Peeper, 2009; Coppé et al., 2010), and autophagy 
(Salama et al., 2014). In addition, senescence is typically accompa-
nied by an enlarged cellular morphology with increased vesicle for-
mation. Senescent nuclei can also display distinct morphological 
changes, including an enlargement of the nuclei and the nucleoli 
(Mitsui and Schneider, 1976; Bemiller and Lee, 1978), formation of 
senescence-associated heterochromatic foci (SAHF; Narita et al., 
2003; Zhang et al., 2005), up-regulation of promyelocytic leukemia 
nuclear bodies both in size and number (Ferbeyre et al., 2000; 
Pearson et al., 2000; Bischof et al., 2002, 2005), alterations of lamin 
B1 and other components of the nuclear envelope (Maeshima et al., 
2006; Barascu et al., 2012; Freund et al., 2012; Dreesen et al., 2013; 
Sadaie et al., 2013; Shah et al., 2013), and alterations of nuclear 
shape (Matsumura et al., 1979; reviewed in Goldstein, 1990; 
Cristofalo and Pignolo, 1993). Hence it has been proposed that it is 
necessary to combine multiple markers, which can be either com-
mon or unique to different contexts. Validation of stable exit from 
the cell cycle is required for the phenotype to qualify as senescence 
(Campisi, 2013; Salama et al., 2014).
Aurora kinase B (AURKB) is a member of the Aurora family, which 
also includes the related kinases AURKA and AURKC. Both AURKA 
and AURKB are ubiquitously expressed, but their subcellular local-
ization, binding partners, and substrates are highly distinctive. The 
different isoforms are thus involved in different aspects of cell cycle 
regulation, whereas AURKC is mainly expressed in testis, and its 
function is not well characterized (Gautschi et al., 2008). Whereas 
AURKA is a centrosomal protein, mainly related to centrosome func-
tion and bipolar spindle assembly, AURKB, the catalytic component 
of the chromosome passenger complex, plays a key role in correct 
chromosomal alignment and segregation by destabilizing errone-
ous kinetochore–microtubule attachments and is believed to be in-
volved in the spindle assembly checkpoint (SAC). It also has a critical 
role in cytokinesis (Kelly and Funabiki, 2009; Lens et al., 2010; 
Carmena et al., 2012). Inhibition of AURKB in cell culture leads to a 
failure to biorient chromosomes and perturbed cytokinesis and, as a 
consequence, causes polyploidization and an eventual loss of viabil-
ity (Ditchfield et al., 2003; Kaestner et al., 2009; Lens et al., 2010). It 
was shown that AURKs inhibitors that are more selective for AURKA 
induce senescence in tumor cells (Huck et al., 2010; Liu et al., 2013). 
On the other hand, it was also shown that the ectopic expression of 
Volume 26 September 1, 2015 Senescence after abortive mitosis | 2973 
Hit compounds identified by the screen are capable 
of inducing cellular senescence
To determine whether the hit compounds induce senescence in 
IMR90 cells, secondary assays were performed for a subset of com-
pounds: those that scored positive, as well as those that showed a 
stronger irregular phenotype (type I) in the screen (Figure 2). To op-
timize the doses of compounds for senescence induction, we tested 
different concentrations of the compounds and chose the doses 
that did not induce substantial cell death (Figure 2A and Supple-
mental Figure S1F). Cells were exposed to these compounds for 4 d 
(d4), followed by a further incubation without the compounds for 
5 d (d9) to examine the phenotype irreversibility, a critical feature of 
senescence.
We confirmed that the majority of IRG-treated cells exhibited 
enlarged and irregular-shaped nuclei after a 4-d treatment and 
these nuclear phenotypes were maintained after the compounds 
obtained when we treated cells with the compounds at 3 μM (Sup-
plemental Figure S1D).
We also manually scored all the compounds by visually inspect-
ing the scanned images. The nuclei from the cells treated with the 
11 size hits were all recognized as substantially enlarged, and the 
spotty nuclei in at least eight of 17 hits-treated cells were confirmed 
by eye. Of interest, in most of the size hits, the nuclei exhibited a 
severe malformation, with a fragmented, cashew nut–like, or dough-
nut-like morphology, often accompanied by multiple micronuclei 
(type I), whereas some showed milder changes and were without 
fragmentation or holes (type II; Figure 1E and Supplemental Figure 
S1E). The size hits also included nuclei without any apparent irregu-
larity (“large”). We termed the hit compounds that induced an ir-
regular nuclear shape and spotty morphologies IRGs and SPTs, re-
spectively, and examined whether these phenotypes are associated 
with cellular senescence.
FIGURE 1: Automated image-based screening for compounds that induce morphological changes in nuclei. (A) Flow of 
the screen. Cells were treated with small-molecule kinase inhibitors for 4 d in 96-well plates, followed by fixation and 
staining with DAPI, and analyzed using an automated image analyzer (ArrayScan), along with a visual inspection by 
fluorescence microscopy. (B) The protocol for automated nuclear image acquisition and analyses was set up using 
normally proliferating and H-RASG12V–induced senescent (RIS) IMR90 cells. Nuclei (DAPI signals) were recognized in the 
first channel (marked with blue contours), and then any spotty pattern was detected in the second channel (marked in 
red). Numbers represent the ratios between RIS and proliferating (Prolif) cells for the indicated features. (C) Score 
distributions of the nuclear average area (left) or the spot total area per nucleus (right) of the cells after 4-d exposure to 
 5 μM compounds. Threshold was set at 1.2-fold (relative nuclear average area) or 3-fold (relative spot total area per 
nucleus) of a DMSO control. (D) Number of the hits identified by the automated detection and subsequent eye 
detection. Cells were treated as in C. Asterisks, toxic compounds that failed to give >100 nuclei count. (E) Representative 
fluorescence images of nuclei of the cells treated with hit compounds by ArrayScan. Enlarged nuclei are categorized into 
three types according to their shape: irregular type I, irregular type II, and large. AP, aminopurvalanol A; Aurora-II, Aurora 
kinase inhibitor II; CDK2-IV, CDK2 inhibitor IV; EGFR, EGFR inhibitor; MK2a, MK2a inhibitor; PDGFR-V, PDGF RTK 
inhibitor V; RhoK-IV, Rho kinase inhibitor IV.
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cells after 2-wk incubation with compound-free medium was 
strongly reduced if they were pretreated with IRGs (Figure 2D), rein-
forcing the long-term nature of the observed cell cycle arrest. To 
further confirm that the IRGs induce senescence, we measured SA-
β-gal activity, a hallmark of senescence (Dimri et al., 1995). Cells 
had been removed (Figure 2A and Supplemental Figure S2). IRGs 
also induced a stable cell cycle arrest, as determined by a reduction 
in cyclin A, the phosphorylation status of RB (Figure 2B), and 
5-bromo-2′-deoxyuridine (BrdU) incorporation (Figure 2C), even af-
ter compound removal. Consistently, the number of colony-forming 
FIGURE 2: “Irregular-shaped” nuclear phenotype is associated with cellular senescence. (A) IMR90 cells were exposed 
to the hit compounds that induce formation of the irregular-shaped nuclei (IRGs) for 4 d (d4), followed by a 5-d 
incubation in compound-free medium (d9). The percentage of cells showing irregular-shaped nuclei at the indicated time 
points was assessed using DAPI staining. (B) Immunoblot analysis for the indicated proteins. RB-ph, phosphorylated RB. 
(C) Percentage of BrdU incorporation–positive cells. (D) For colony formation assay, cells were plated without compounds 
after a 4-d treatment with IRGs. (E) SA-β-gal activity in the compound-free cells (d9). (F) Cells indicated were assessed for 
SAHF formation. Values are mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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recent reports that demonstrated a senescence-associated lamin B1 
reduction (Shimi et al., 2011; Salama et al., 2014), lamin B1 was 
down-regulated in IRG-treated cells (Supplemental Figure S3, A and 
B). Of note, induction of the irregular nuclear shape in IRG-treated 
cells preceded lamin B1 reduction (Supplemental Figure S3C), sug-
gesting that the lamin B1 reduction is not the cause of the irregular 
nuclei. These compounds also induced senescence in BJ cells (an-
other HDF), although some compounds induced a milder pheno-
type than in IMR90 cells (Supplemental Figure S4).
Similarly to IRGs, we also tested selected SPT hits in the second-
ary senescence assays. These compounds were more toxic than the 
IRGs, and we used a lower concentration for our validation experi-
ments. At the concentrations used (Figure 3A), the viability of cells 
pretreated with the IRGs typically showed an enlarged cellular mor-
phology with increased SA-β-gal activity (Figure 2E). Although the 
levels of p16, a senescence-associated CDK inhibitor, were unal-
tered, p53 and its target p21 (another CDK inhibitor), both of which 
play important roles in senescence in some contexts (Chang et al., 
2000, 2002), were stably upregulated in IRG-treated cells (Figure 
2B). Of interest, the levels of HMGA2, a senescence marker associ-
ated with SAHFs (Funayama et al., 2006; Narita et al., 2006), were 
increased only at the later time point. Consistently, SAHF formation 
was also more evident at d9 (Figure 2F), and thus senescence is 
progressively established even during the compound-free period. 
These results suggest that senescence is not an immediate outcome 
of the treatment but rather a delayed phenotype. Consistent with 
FIGURE 3: “Spotty” nuclear phenotype is associated with cellular senescence. (A) Cells were assessed for formation 
of a spotty nucleus using immunofluorescence. Right, confocal images of the cells immunostained for histone H3 
trimethylated at lysine 9 (H3K9me3) and H3K36me3, markers of heterochromatin and euchromatin, respectively, and 
counterstained with DAPI. DAPI foci were colocalized with H3K9me3. (B) Immunoblot analysis in the compound-treated 
cells using the indicated antibodies. (C) Percentage of BrdU incorporation–positive cells. (D) After a 4-d treatment with 
the SPTs, cells were plated without the compounds in equal number for the colony formation assays. (E) SA-β-gal 
activities in the indicated cells at d9.*p < 0.05, **p < 0.01.
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immediately after M phase without proper chromosome segrega-
tion and that cell cycle arrest at the G1 tetraploid phase is main-
tained during senescence development in normal HDFs.
Premature exit from M phase without chromosome segregation 
takes place after prolonged mitosis (mitotic slippage; Gascoigne 
and Taylor, 2009) or when the spindle checkpoint is restrained (Vitale 
et al., 2011). Inhibition of microtubule dynamics by paclitaxel (Taxol; 
a microtubule-stabilizing agent) activates the mitotic checkpoint to 
keep cells arrested at the metaphase/anaphase boundary, at which 
the well-known mitosis marker histone H3 phosphorylated at serine 
10 (H3S10ph), a direct substrate of AURKB and cyclin B, accumu-
lates (Figure 4E, lane 2). It has been shown that treatment with 
AURKB inhibitors overrides the paclitaxel-induced SAC (Ditchfield 
et al., 2003; Hauf et al., 2003). To test whether treatment with the 
IRGs also cancels the paclitaxel-induced SAC, we synchronized 
IMR90 cells with paclitaxel treatment for 12 h and then released cells 
into paclitaxel with or without IRGs or ZM1 (Figure 4E). Similar to 
ZM1 (Figure 4E, lane 9), the paclitaxel-induced checkpoint was rap-
idly canceled by the addition of each of the IRGs (Figure 4E, lanes 
4–8), whereas accumulation of cyclin B1 and H3S10ph was virtually 
unaffected by the treatment with SPTs (Supplemental Figure S6, 
lanes 10–12). These results further support our hypothesis that treat-
ment with IRGs induces the irregular nuclear phenotype with tetra-
ploidization through AURKB inhibition.
It has been shown that AURKB inhibition does not have a sub-
stantial effect on the viability of nonproliferating cells (Ditchfield 
et al., 2003; Hardwicke et al., 2009). To study whether cell cycle pro-
gression is required for IRGs to induce senescence, we treated qui-
escent IMR90 cells, induced by serum starvation, with the com-
pounds for 3 d (Supplemental Figure S7A). We then released the 
compound-treated cells from quiescent arrest into compound-free 
normal medium (10% serum). The pretreated cells (during quies-
cence) failed to change their nuclear morphology (Supplemental 
Figure S7, A and B) and exhibited virtually no reduction in their pro-
liferative capacity (Supplemental Figure S7C). Therefore IRGs and 
ZM1 induce senescence in proliferating but not in nonproliferating 
cells. Together these results suggest that, although these com-
pounds have multiple targets, the downstream effects may con-
verge on AURKB, which appears to be the dominant pathway for 
their senescence-inducing activity.
Specific inhibition of Aurora B kinase activity triggers 
formation of irregular-shaped nuclei and cellular senescence
We next tested whether the IRGs directly inhibit AURKB kinase ac-
tivity, using a biochemical kinase profiling assay. Consistent with the 
phenotypic similarity between IRGs and ZM1 treatment, all five IRGs 
exhibited a substantial inhibitory effect against AURKA and AURKB, 
with stronger effects on AURKB, whereas the SPT hits showed virtu-
ally no effect on the activities of the AURKs (Figure 5A). Although 
ZM1-induced polyploidization has been attributed to AURKB inhibi-
tion (Ditchfield et al., 2003; Hauf et al., 2003; Girdler et al., 2006), 
ZM1 also inhibits AURKA, which has both a very distinct localization 
pattern and functions differently from AURKB, and, in addition to 
the AURKs, IRGs have multiple targets.
To suppress specifically AURKB activity, we next sought to apply 
either a stable RNA interference (RNAi) or a dominant-negative ap-
proach. Using a microRNA (miR30)-based design (Silva et al., 2005), 
we identified at least two sh-AURKB constructs that substantially 
down-regulated the endogenous levels of AURKB and induced com-
parable phenotypes in IMR90 cells when stably transduced (Supple-
mental Figure S8). We also generated retroviral constructs encoding 
either an enhanced green fluorescent protein (EGFP)–tagged 
24 h after drug treatment was >90% (Supplemental Figure S1F). Al-
though the nuclear phenotype was relatively modest compared with 
the IRG hits, the formation of DAPI foci was significantly increased 
after treatment with the SPT hit compounds (Figure 3A). These foci 
were colocalized with H3K9me3 but excluded H3K36me3 and are 
thus morphologically similar to SAHFs. Consistently, p21 and p16, 
which have been shown to be effectors of SAHF formation, were 
both up-regulated (Figure 3B). Cells pretreated with these com-
pounds were stably arrested and displayed additional features of 
senescence (Figure 3, B–E). Together our data provide a proof of 
principle that the nuclear phenotypes can be used as a readout for 
prosenescence screens. For further validation of the compounds 
and nuclear phenotypes in the context of senescence in this study, 
we decided to focus on IRGs and their associated phenotype, which 
were strong and highly distinctive.
IRG compounds induce premature exit from M phase 
and tetraploidization
To examine at which cell cycle stage the IRG-treated cells accumu-
late and become senescent, we analyzed cell cycle profiles and the 
expression pattern of cyclins by laser scanning cytometer and im-
munoblotting, respectively. After treatment with IRGs, the number 
of cells with a 4n DNA content became markedly increased com-
pared with mock-treated cells (Figure 4A). In addition there was an 
increase in the number of cells with an 8n DNA content. Of interest, 
immunoblot analysis showed that those cyclins enriched in G2 or M 
phase (cyclin A or B1, respectively) were decreased, whereas a G1 
cyclin (cyclin D1) was increased during IRG-induced senescence 
(Figure 4B). These data suggest that the increased 4n DNA content 
reflects cell cycle arrest in G1 phase after a failed mitosis (i.e., a tet-
raploid state) rather than G2 arrest. This is highly reminiscent of 
Aurora kinase B (AURKB) inhibitors, which induce irregular-shaped 
nuclear formation with polyploidization (Ditchfield et al., 2003; Hauf 
et al., 2003). Indeed, the IRGs included some compounds (Aurora 
kinase inhibitor II and SU6656) that can inhibit AURK (Bain et al., 
2007). Therefore we tested whether the inhibition of AURKB activity 
by ZM1 (ZM447439; Girdler et al., 2006), a well-established AURKB 
inhibitor, causes cellular senescence in HDFs. Treatment of both 
IMR90 and BJ cells with ZM1 phenocopied the IRG effect. Consis-
tent with the previous studies, ZM1 treatment induced tetraploidy 
with a highly irregular nuclear shape (Figure 4, A–C). Detailed senes-
cence assays confirmed that ZM1-pretreated cells exhibited a stable 
exit from the cell cycle with increased senescence markers (Figure 
4C). Similar to cells exposed to IRG compounds, ZM1-treated cells 
ceased to proliferate by d4, at which point they had irregular nuclei 
and were mostly tetraploid. However, the establishment of senes-
cence again appeared to be delayed, steadily developing beyond 
the 4d treatment (Figure 4C; see SAHF count and HMGA2 blotting). 
Similar results were obtained using AZD1152, another specific in-
hibitor of AURKB (Wilkinson et al., 2007; Supplemental Figure S5). 
Together these data suggest that IRG compounds may induce se-
nescence at least in part by directly or indirectly inhibiting AURKB 
activity.
To confirm directly the correlation between irregular nuclei and 
tetraploidy, we tracked the fate of mitotic nuclei by live-cell imaging 
of cells expressing H2B:enhanced yellow fluorescent protein (EYFP) 
that had been treated with the compounds. As shown in Figure 4D, 
cells treated with the compounds entered M phase and condensed 
their chromosomes, yet they eventually decondensed without 
proper segregation and formed mostly single and irregular-shaped 
nuclei (Figure 4D, Supplemental Movies S1–S3, and Supplemental 
Table S4). These data suggest that the irregular-shaped nuclei arise 
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cells expressing AURKBD218N or treated with ZM1 (Figure 5B), per-
haps due to the cell cycle arrest in the tetraploid G1 phase caused by 
AURKB inhibition (Gully et al., 2012). Immunoblot analysis showed 
wild-type or a kinase-dead AURKB mutant (AURKBD218N), which was 
previously shown to function in a dominant-negative manner (Girdler 
et al., 2006). Endogenous AURKB levels were also down-regulated in 
FIGURE 4: Aurora kinase inhibition phenocopies IRG treatment in IMR90 cells (A) Cell cycle profiles of the cells treated 
as in Figure 2A were analyzed by laser scanning cytometry. In addition to IRG hits, the AURKB inhibitor ZM1 (2 μM; Z) 
was included. (B) Accumulation of a G1-phase cyclin in the IRG- or ZM1-treated cells. (C) ZM1 treatment induces 
senescence in IMR90 cells. Cells treated as in A were assessed for nuclear morphology, BrdU incorporation, SAHF 
formation, SA-β-gal activities, expression of indicated proteins, and colony formation. **p < 0.01, ***p < 0.001. 
(D) Time-lapse images of the nuclei in compound-treated cells expressing H2B-EYFP (see Supplemental Movies S1–S3). 
Compounds were added when the cells were released from G1/S, and the first mitoses were recorded. (E) Treatment of 
cells with IRGs elicits exit from paclitaxel-induced M-phase arrest. IMR90 cells were synchronized in M phase by 
paclitaxel (P) for 12 h, and the indicated hit compounds were added and incubated for 2 h. For comparison, we also 
used the spotty hit compounds, which failed to induce a premature exit from the paclitaxel-induced M-phase arrest 
(lanes 10–12 [see Supplemental Figure S6]). M-phase cells were assessed using the levels of cyclin B1 and histone H3 
phosphorylation at serine 10 (H3S10ph; a direct substrate of AURKB). The blots for cyclin B1 and H3S10ph in the 
paclitaxel-treated cells (left) were run in the same gel (see full lanes in Supplemental Figure S6).
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tion induced irregular-shaped nuclei at a similar frequency in both 
control and sh-p53–expressing cells (Figure 6, B and C). However, 
the nuclear phenotype of the sh-p53–expressing cells was highly 
heterogeneous, and nuclear enlargement was more pronounced 
than in control cells (Figure 6, B and E). Reduction of BrdU incorpo-
ration was partially rescued by p53 depletion, with a corresponding 
increase in the polyploid population (Figure 6, C and D). These re-
sults are consistent with previous studies suggesting that deficien-
cies in the p53-p21 pathway enhance the endoreduplication caused 
by Aurora kinase inhibitors (Ditchfield et al., 2003; Gizatullin et al., 
2006; Kaestner et al., 2009). Accumulation of SA-β-gal activity and 
reduced long-term proliferative capacity were also partially rescued 
by p53 knockdown (Figure 6, F and G). These results suggest that 
p53 is not required for the irregular nuclear phenotype but that the 
overall senescence phenotype is partially dependent on p53.
IRG compounds block the proliferation of cancer cells
AURKB inhibition in tumor cells leads to increased polyploidy and 
cell cycle arrest or cell death, depending on the cell type or context 
(Ditchfield et al., 2003; Hauf et al., 2003; Gizatullin et al., 2006; 
Wilkinson et al., 2007; Yang et al., 2007). For example, in the pres-
ence of AURKB inhibitors, HeLa cervical carcinoma cells enter and 
exit mitosis normally but fail to divide (Ditchfield et al., 2003; Hauf 
et al., 2003). However, long-term senescence development in tumor 
that expression of AURKBD218N or sh-AURKB-1 or ZM1 treatment re-
sulted in a reduction in H3S10ph (Figure 5B). Cyclin A, cyclin B1, and 
phosphorylated RB were down-regulated, whereas cyclin D1 (a G1 
cyclin) was increased in AURKBD218N- or sh-AURKB-1–expressing 
cells, as observed in IRGs/ZM1-treated cells (Figure 5B; also Figure 
4B). The nuclear phenotype with irregular shape was comparable 
between AURKBD218N-expressing cells and ZM1-treated cells, 
whereas sh-AURKB-1–expressing cells showed a milder phenotype 
(Figure 5C). Consistently, the senescence phenotype was also milder 
in the sh-AURKB-1–expressing cells (Figure 5, B–D). Of note, cells 
expressing sh-AURKB-1 exhibited residual H3S10ph (Figure 5B), and 
thus the milder phenotype of sh-AURKB-1–expressing cells might be 
due to a residual activity of AURKB (see also Supplemental Figure 
S8, A and B, for a dose-dependent correlation between AUKB1 
levels and proliferative arrest). Together these results indicate that 
AURKB inhibition–induced senescence progressively develops in 
tetraploid cells with a highly irregular nuclear morphology and is an 
immediate consequence of AURKB inhibition in normal HDFs.
Knockdown of p53 partially rescues IRG-induced 
senescence in IMR90 cells
We next tested whether IRG-induced senescence is dependent on 
p53 in IMR90 cells, using a miR30 design–based RNAi-mediated 
knockdown of p53 (Figure 6A; Kirschner et al., 2015). AURKB inhibi-
FIGURE 5: Specific inhibition of Aurora B kinase activity induces cellular senescence. (A) In vitro kinase activity assay. 
The IC50 of the indicated compounds was determined using an in vitro kinase activity assay for AURKA or AURKB. 
(B–D) Genetic inhibition of AURKB activity induces cellular senescence. IMR90 cells were stably transduced with 
retroviral vectors expressing EGFP-tagged wild-type (Wt) or kinase-dead dominant-negative (DN) mutant (AURKBD218N) 
AURKB, sh-AURKB-1 (sh-1; Supplemental Figure S8), or corresponding controls (V; EGFP or miR30 vector, respectively). 
Cells were also treated with ZM1 (Z) or DMSO (–) for comparison (d9). At d6 after retroviral infection and selection, cells 
were assessed for protein expression (B) and irregular-shaped nuclei, BrdU incorporation, and SA-β-gal activity (C). 
Values are mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. Cells were also plated 
at the same density and assessed for colony formation (D).
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5-d incubation in compound-free medium, however, cells exhibited 
an accumulation of the G1 cyclin (cyclin D1) and reduced markers of 
cell cycle progression, such as the S/G2 cyclin (cyclin A), phosphory-
lated forms of RB, and BrdU incorporation (Figure 7, B and C), sug-
gesting that the compound-pretreated cells eventually arrest at a 
polyploid G1 phase. These cells also showed a robust accumulation 
of SA-β-gal activity (Figure 7, D and E). Thus the IRG compounds 
can induce senescence in HeLa cells. Their long-term arrest was 
confirmed using colony formation assays in compound-free me-
dium (Figure 7F). Of interest, we found that the p53-p21 pathway 
and HMGA2 were up-regulated, particularly at d9 (Figure 7B). Note, 
however, that in HeLa cells, the level of wild-type endogenous p53 
cells pretreated with AURK inhibitors remains to be determined. To 
test whether these compounds cause TIS in tumor cells, we treated 
HeLa cells with selective IRGs as well as ZM1. We first confirmed 
that cells were mostly viable (∼80% at day 9; Supplemental Figure 
S9A) after treatment with the compounds at the concentrations 
used. Consistent with the phenotype of AURKB inhibition, after a 
4-d treatment with these compounds, the cells contained remark-
ably enlarged and highly irregular/multilobulated nuclei or often 
had numerous nuclei per cell (Figure 7A). At this stage, the cells 
showed only a modest retardation of cell cycle progression with lit-
tle sign of senescence (probed through phosphorylation status of 
RB and BrdU incorporation; Figure 7, B and C). After an additional 
FIGURE 6: Effect of p53 knockdown on IRG compound–induced senescence in IMR90 cells. (A) Immunoblot analysis for 
the indicated proteins in cells expressing sh-p53 or control vector, which were treated with RhoK-IV (R), ZM1, or DMSO 
(–) for 4 d (d4), followed by a 5-d culture in compound-free medium (d9). (B) Fluorescence (DAPI) images of the indicated 
cells treated as in A at d9. (C) Percentage of indicated cells with irregular-shaped nuclei or BrdU incorporation at the 
indicated time points. R, RhoK-IV; Z, ZM1; –, DMSO. Values are the mean ± SEM from three independent experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001. (D, E) Cell cycle profiles (D) and nuclear area size (E) of the indicated cells treated as 
in A were analyzed by laser scanning cytometry at d9. (F) SA-β-gal activity in the indicated cells at d9. Values are the 
mean ± SEM from three independent experiments. ***p < 0.001. (G) Colony formation assays for the indicated cells 
pretreated with the indicated compounds for 4 d.
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that the IRG/ZM1-pretreated cells also de-
velop the G1 polyploid phenotype. Al-
though the reduction in DNA synthesis and 
cyclin A levels was less pronounced than in 
HeLa cells at d9, the pretreated H1299 cells 
showed a strong senescence-like pheno-
type (Figure 8D) with a marked reduction in 
their colony-forming capacity, likely due to a 
combination of senescence and cell death 
(Figure 8E). Of interest, p21 up-regulation 
was observed at later time points in H1299 
cells, suggesting the existence of a p53-in-
dependent mechanism for p21 induction in 
this context (Figure 8B; Macleod et al., 
1995). Taken together, our data suggest that 
AURKB inhibition triggers senescence and 
that this senescence develops while the 
cells are in a tetraploid state or, in the case 
of the tumor cells with reduced or defective 
p53, a polyploid state.
DISCUSSION
Although the primary endpoint of conven-
tional chemotherapy is generally cell death, 
senescence is gaining increasing attention 
as an alternative goal in cancer therapy 
(Acosta and Gil, 2012; Cairney et al., 2012). 
Senescence is a heterogeneous and collec-
tive phenotype mediated by multiple effec-
tor programs, which are often associated 
with distinct senescence markers (Salama 
et al., 2014). This predicts the benefit of us-
ing diverse markers as readouts in screens 
for senescence inducers and/or senescence 
bypass. Here we focus on nuclear/chromatin 
morphological alterations, allowing us to 
identify multiple compounds that induce 
“tetraploid senescence,” likely through a di-
rect inhibition of AURKB in a progressive 
manner. Indeed, a small 8n cell population 
can be seen in conventional RAS-induced 
senescent cells (Supplemental Figure S1), 
suggesting that our screen simply captured 
an enrichment of certain subtypes of the se-
nescence phenotype. Of importance, such a 
system of “high-content” analyses could be 
extended through additional readouts and also allows for flexible 
strategies, which could be targeted at broader, or tuned for specific, 
senescence effector programs. Although, as a proof of principle, we 
used normal HDFs, which are highly prone to senescence, and a ki-
nase inhibitor library with a modest specificity and diversity (160 in-
hibitors), some of the hits were capable of inducing senescence in 
tumor cell lines. Thus the system is potentially applicable to TIS 
screening, with higher throughput and/or different types of libraries. 
Although our data indicate that IRGs induce senescence through 
AUKB inhibition, it is important to note that additional “on-target” 
effects of such multitarget inhibitors might confer additional effects 
on and/or modulate their AURKB inhibitory activity.
The Aurora kinases are overexpressed in a wide range of human 
cancers and are considered as promising therapeutic targets, and a 
number of clinical trials are at various stages (Keen and Taylor, 2004; 
Green et al., 2011; Goldenson and Crispino, 2015). These studies 
is suppressed by human papillomavirus E6, it has been shown that 
p53 can escape from its E6-mediated down-regulation upon stress 
in some contexts (Wesierska-Gadek et al., 2002; Li and Anderson, 
2014), and our data suggest that treatment with these compounds 
is also able to restore endogenous p53 levels in the presence of E6 
as a long-term effect, further reinforcing the progressive nature of 
senescence establishment after removal of the compounds.
We next asked whether these compounds induce senescence in 
tumor cells that completely lack p53, using H1299, a p53-null hu-
man lung cancer cell line. Although some rounded-up or floating 
cells were observed at both d4 and d9, IRG-treated H1299 cells 
were largely viable (Supplemental Figure S9B). Similar to HeLa cells, 
the cells that were attached exhibited highly enlarged irregular/
lobulated nuclei and/or a multinuclear phenotype (Figure 8A), the 
progressive accumulation of G1 cyclin (cyclin D1) (Figure 8B), and a 
significant reduction in BrdU incorporation (Figure 8C), suggesting 
FIGURE 7: HeLa cells undergo cellular senescence by treatment with IRGs. (A) Fluorescence 
(DAPI) images of HeLa cells treated with selected IRG compounds and ZM1 for 4 d, followed by 
a 5-d culture in compound-free medium (d9) as in Figure 2A. RhoK-IV, Cdk2-IV, and ZM1 were 
used at 1.5, 4, and 1.5 μM, respectively. DNA was stained with DAPI. Numbers represent 
percentages of nuclei with an irregular shape (d9). (B) Immunoblot analysis for the indicated 
proteins in HeLa cells at d4 and d9. (C) Percentage of cells that are BrdU incorporation positive. 
(D, E) SA-β-gal assays for the compound-pretreated HeLa cells at d9; representative images 
(D) and quantitative data (E). *p < 0.05, **p < 0.01, ***p < 0.001. (F) Colony formation assays in 
HeLa cells pretreated with indicated compounds for 4 d. Values are mean ± SEM from three 
independent experiments.
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ploidization and senescence was not exam-
ined (Johmura et al., 2014; Krenning et al., 
2014).
Tetraploid cells are suggested to be ge-
netically unstable and have a risk of produc-
ing aneuploidy, a hallmark of cancer cells 
(Fujiwara et al., 2005; Ganem et al., 2007; 
Storchova and Kuffer, 2008; Davoli et al., 
2010). It has been controversial whether a 
p53-dependent G1 “tetraploidy check-
point,” which senses an excessive number 
of chromosomes or centrosomes, exists 
(Andreassen et al., 2001; Margolis et al., 
2003; Uetake and Sluder, 2004; Wong and 
Stearns, 2005; Hayashi and Karlseder, 
2013). Of interest, however, Ganem et al. 
(2014) recently showed that tetraploidiza-
tion can trigger a “G1 arrest” without an 
apparent DNA-damage response, through 
the activation of the Hippo and p53 path-
ways. It would be very interesting to test 
whether AURKB inhibition-induced senes-
cence is, at least in part, dependent on 
these pathways.
Our data suggest that senescence is a 
delayed process rather than an immediate 
consequence of tetraploidization. Although 
a polyploid chromosome number might 
contribute to inducing senescence by itself, 
it is also possible that the pathophysiology 
behind polyploidization could progressively 
provoke senescence effector mechanisms. 
Indeed, both senescence and tetraploidy 
are associated with some common patho-
physiological contexts, including wound 
healing, aging, preneoplasia, and embry-
onic development (Ermis et al., 1998; 
Ganem et al., 2007; Davoli and de Lange, 
2011; Gentric et al., 2012; Chuprin et al., 
2013). Although the p53-defective cells 
treated with the AURKB inhibitor under-
went substantial endoreduplication and 
became highly polyploid, we saw only a 
partial progression to senescence in these 
cells (Figures 6–8), and some senescence 
escape was observed, particularly in normal 
cells (Figure 6). However, it remains unclear 
whether, in p53-defective conditions, a small fraction of the cells 
that escaped from the initial mitotic defect eventually grew out or 
whether some polyploid senescent cells resumed a normal cell 
cycle.
Persistent senescent cells in vivo may contribute to tumorigene-
sis through the SASP, particularly in TIS conditions (Coppé et al., 
2010; Jackson et al., 2012; Dörr et al., 2013). Of interest, typical 
SASP factors, including MMP3, IL6, and IL8 were not induced in 
AURKB inhibition–induced senescent cells (Supplemental Figure 
S10). Although more detailed analyses would be required, our data 
suggest that AURKB inhibition might provide a unique therapeutic 
opportunity, which alleviates the non–cell-autonomous tumorigenic 
effects of senescence. Of note, the SASP is also involved in the im-
mune-mediated elimination of senescent cells (Xue et al., 2007; 
Kang et al., 2011), and without this step, “unstable” senescent cells 
are aimed at inducing cell death, and the induction of a senescence-
like response has not been considered in these trials.
Inhibition of AURKB overrides the SAC, thereby inducing a pre-
mature exit from mitosis and interfering with cytokinesis, leading to 
tetraploid/binuclear cells (Keen and Taylor, 2009). However, how 
AURKB inhibition develops into a senescence phenotype in the tet-
raploid condition remains to be elucidated. Tetraploidization can 
also be induced by mitotic slippage after a prolonged mitosis, cyto-
kinesis failure, endoreduplication, telomere dysfunction, DNA- 
damaging agents, or cell fusion (Storchova and Kuffer, 2008; Davoli 
et al., 2010; Davoli and de Lange, 2011; Johmura et al., 2014; 
Panopoulos et al., 2014). In addition, it was recently shown that “mi-
totic skip” is involved in tetraploid senescence, particularly when 
induced by DNA damage, in which p53 activation during G2 plays 
a key role, although possible functional relation between tetra-
FIGURE 8: p53-null cancer cells undergo cellular senescence by treatment with IRGs. (A) Phase 
contrast and DAPI images of H1299 cells treated with selected IRG compounds and ZM1 for 
4 d, followed by a 5-d culture in compound-free medium (d9) as in Figure 2A. (B) Immunoblot 
analysis for the indicated proteins in H1299 cells at d4 and d9. (C) Percentage of the BrdU 
incorporation–positive cells. (D) SA-β-gal assays for the compound-pretreated H1299 cells at d9; 
representative images (D) and quantitative data (E). Values are mean ± SEM from three 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. (E) H1299 cells pretreated with 
the indicated compounds for 4 d were maintained in normal media for colony formation assay.
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(+0.2% Triton X-100) for 5 min. Images of the nuclei were captured 
and analyzed by ArrayScan (Thermo Scientific, Waltham, MA) with 
the settings shown in Supplemental Table S1. Briefly, nuclear con-
tour was first determined (channel 1), and then spotty structures 
overlapping with the nuclei were identified (channel 2). Longer and 
shorter exposure times with the same filter set were applied for the 
channels 1 and 2, respectively. To rank the compounds by nuclear 
size and spottiness, the parameters Relative Nuclear Average Area 
and Relative Spot Total Area per Nucleus over DMSO control were 
used for the analyses, respectively. The compounds that gave a 
count of <100 nuclei/well were categorized as toxic and excluded 
from analyses. Hit compounds from each category were further nar-
rowed and recategorized by visual inspection.
Compounds
The final concentrations used for the compound were as follows. 
For HDFs and H1299 cells, Aurora kinase inhibitor II, 8 μM (CAS# 
331770-21-9; 189404; Merck); Cdk2 inhibitor IV, NU6140, 4 μM 
(CAS# 444723-13-1; 238804; Merck); PDGFR tyrosine kinase inhibi-
tor V, 8 μM (CAS# 347155-76-4; 521234; Merck); Rho kinase inhibi-
tor IV, 10 μM (555554, Merck; or CAS# 913844-45-8; 2485, Tocris, 
Bristol, UK); SU6656, 10 μM (CAS# 330161-87-0; 572635; Merck); 
ZM1 (ZM-447439), 2 μM (CAS# 331771-20-1; sc-200696, Santa Cruz 
Biotechnology); EGFR inhibitor, 0.5 μM (CAS# 879127-07-8; 324674; 
Merck); JNK inhibitor IX, 0.5 μM (CAS# 312917-14-9; 420136, 
Merck); MK2a inhibitor, 0.7 μM (CAS# 41179-33-3; 475863, Merck); 
and AZD1152-HQPA, 0.5 μM (CAS# 722544-51-6; SML0268, Sigma-
Aldrich). For HeLa cells, Rho kinase inhibitor IV, Cdk2 inhibitor IV, 
and ZM1 were used at concentrations of 1.5, 4, and 1.5 μM, respec-
tively. Nocodazole, 200 ng/ml (CAS# 31430-18-9; 487928; Merck); 
paclitaxel, 10 μM (CAS# 33069-62-4; T7402; Sigma-Aldrich).
Senescence and viability assays
Cells were treated with the hit compounds for 4 d (d4), followed by 
5-d incubation in compound-free medium (d9) unless stated other-
wise. BrdU incorporation, SA-β-gal, and colony formation assays 
were conducted as described (Narita et al., 2003). The primary 
antibody for BrdU incorporation was 555627 (Becton Dickinson, 
Franklin Lakes, NJ). Cell viability was determined by trypan blue 
exclusion.
Immunofluorescence and laser scanning cytometer
Immunofluorescence was performed as described (Narita et al., 
2003). Primary antibodies were H3K9me3 (07-523; Millipore), 
H3K36me3 (13C9; Chandra et al., 2012), LMNA (sc-20680; Santa 
Cruz Biotechnology), LMNA/C (sc-7292; Santa Cruz Biotechnology), 
LMNB1 (ab16048; Abcam), and α-tubulin (T5168, Sigma-Aldrich). 
Images were acquired with confocal (when stated) or wide-field fluo-
rescence microscopy. LSC (iCys; Compucyte, Westwood, MA) was 
used to determine cell cycle profile and nuclear size distribution.
Live-cell imaging
IMR90 cells stably expressing histone H2B:EYFP were synchronized 
at the G1/S border using a double-thymidine treatment. Briefly, 
cells were plated at a density of 1.76 × 104 cells (in 300 μl of me-
dium) per well onto an eight-well μ-slide (80826; ibidi, Martinsried, 
Germany). One day after plating, the medium was replaced with 
one containing 2 mM thymidine and incubated for 14 h. Cells were 
washed three times with 200 μl of prewarmed PBS and released into 
thymidine-free medium for 12 h. Then the cells were again incu-
bated 13 h in the medium containing thymidine. These synchro-
nized cells were washed three times with 200 μl of prewarmed PBS 
may recur (Kang et al., 2011). Of interest, the fate of senescence 
“escapers” has been linked to “mitotic catastrophe,” a distinct form 
of cell death that occurs soon after mitotic failure by poorly under-
stood mechanisms (Shay and Wright, 2005; Vitale et al., 2011; 
Hayashi and Karlseder, 2013). The mitotic catastrophe and cell 
death after senescence escape have also been associated with defi-
ciencies in the p53-p21 pathway in tumors (Chang et al., 2000; Shay 
and Roninson, 2004; Yun et al., 2009), reinforcing the therapeutic 
relevance of prosenescence cancer therapy using SAC modulators. 
Together with their cell-autonomous activity, such potential backup 
interactions between senescence and cell death through mitotic ca-
tastrophe might provide additional justification for AURKB inhibitors 
or other SAC modulators as a therapeutic module in cancer.
MATERIALS AND METHODS
Cell culture and gene transfer
IMR90 and BJ human fibroblasts (American Type Culture Collection 
[ATCC], Manassas, VA) were cultured in phenol red–free DMEM with 
10% fetal bovine serum (FBS) under 5% oxygen as described previ-
ously (Young et al., 2009). HeLa and H1299 cells (ATCC) were 
cultured in phenol red–free DMEM with 10% FBS. Retroviral gene 
transfer was carried out as described (Narita et al., 2006). RAS-
induced senescence was triggered by the addition of 4-hydroxy-
tamoxifen to cells expressing H-RASG12V fused to the estrogen 
receptor ligand-binding domain (ER:RAS; Young et al., 2009). 
Quiescence was induced by incubating cells in DMEM with 0.1% 
serum for 3 d.
Plasmids
The following retroviral plasmids were used: pLNCX2 (ER:H-
RASG12V [ER:RAS]; Young et al., 2009), pWZL-hygro (EGFP, 
EGFP:AURKB, EDFP:AURKBD218N). miR30-based short hairpin RNA 
was expressed from pMSCV-puro (sh-AURKB, sh-p53; Silva et al., 
2005). The following target sequences were used for pMSCV-
miR30-AURKB: gaagggatccctaactgtt (#1), tttgtttaataaaggctga (#2), 
ggtccctgtcattcactcg (#3), and actgttcccttatctgtt (#4). Sh-p53 was 
previously described as sh-p53#2 (Kirschner et al., 2015).
Antibodies
Antibodies used for Western blotting were as follows: cyclin A 
(C4710; Sigma-Aldrich, St. Louis, MO), cyclin B1 (4135; Cell Signal-
ing, Beverly, MA), cyclin D1 (2926; Cell Signaling), p16 (sc-759; 
Santa Cruz Biotechnology, Dallas, TX), p21 (sc-397; Santa Cruz Bio-
technology), p53 (sc-126; Santa Cruz Biotechnology), HMGA2 (sc-
30223; Santa Cruz Biotechnology), H3S10phos (ab14955; Abcam, 
Cambridge, UK), histone H3 (ab1791; Abcam), AURKB (ab2254; 
Abcam), β-actin (A5441; Sigma-Aldrich), Rb (9309; Cell Signaling), 
LMNA/C (sc-7292; Santa Cruz Biotechnology), LMNB1 (ab16048; 
Abcam), IL-6 (MAB2061; R&D Systems, Minneapolis, MN), IL-8 
(MAB208, R&D Systems), and MMP3 (a kind gift from Gillian Mur-
phy, University of Cambridge, Cambridge, United Kingdom; Allan 
et al., 1991).
Compound screening
IMR90 cells were plated in a 96-well plate (353948; BD Falcon, 
Franklin Lakes, NJ) at 10,000 cells/well. After 24 h, the medium was 
replaced by those containing 3 or 5 μM kinase inhibitors (Inhibi-
torSelect kinase inhibitor library including 160 compounds; Calbio-
chem/Merck, Darmstadt, Germany). At 4 d after compound addi-
tion, cells were washed with phosphate-buffered saline (PBS), fixed 
in PBS with 4% paraformaldehyde for 15 min, and washed with PBS 
three times. Fixed cells were stained with 1 μg/ml DAPI in PBS 
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and released into medium containing the compounds. Ten hours 
later, imaging was started and continued for ∼5 h (5-min intervals) 
with an Eclipse TE2000 PFS Color microscope (Nikon, Tokyo, 
Japan). Conditions for the imaging were as follows: 10× objective; 
three focal planes, 3 μm apart; three fields per well; exposure time 
for bright field, 20 ms, and for YFP, 400 ms; gain, 13.6×; and ND 
filter, 1. Movie and individual files were processed by NIS-Elements 
software and ImageJ 1.48s (National Institutes of Health, Bethesda, 
MD).
In vitro kinase assay
The IC50 of the compounds was identified using a Z’-LYTE in vitro 
kinase assay and was carried out by the SelectScreen biochemical 
kinase profiling service (Invitrogen, Carlsbad, CA). The assay was 
conducted at 10 points from 1 nM to 2 mM with the ATP concentra-
tion 10 μM for AURKA and 81 μM for AURKB.
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